Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
NCT06447662 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this study is to learn about the safety and effects of the study medicine alone or when given together with other anti-cancer therapies. This study also aims to find the best dose. This study is seeking participants who have solid tumors (a mass of abnormal cells that forms a lump or growth in the body) that: * are advanced (cancer that doesn't disappear or stay away with treatment) and * have a KRAS gene mutation (a change in the DNA of the KRAS gene that can cause cells to grow in very high numbers). This includes (but limited to) the following cancer types: Non-Small Cell Lung Cancer (NSCLC): It's a type of lung cancer where the cells grow slowly but often spread to other parts of the body. Colorectal Cancer (CRC): This is a disease where cells in the colon (a part of large intestine) or rectum grow out of control. Pancreatic ductal adenocarcinoma (PDAC): This is a cancer that starts in the ducts of the pancreas but can spread quickly to other parts of the body. Pancreas is a long, flat gland that lies in the abdomen behind the stomach. Pancreas creates enzymes that help with digestion. It also makes hormones that can help control your blood sugar levels. All participants in this study will take the study medication (PF-07934040) as pill by mouth twice a day repeating for 21-day or 28-day cycles. Depending on which part of the study participants are enrolled into they will receive the study medication (PF-07934040 alone or in combination with other anti-cancer medications). These anti-cancer medications will be given in the study clinic by intravenous (IV) that is directly injected into the veins at various times (depending on the treatment) during the 21-day or 28-day cycle. Participants can continue to take the study medication (PF-07934040) and the combination anti-cancer therapy until their cancer is no longer responding. The study will look at the experiences of people receiving the study medicines. This will help see if the study me
Conditions Studied
Interventions
- COMBINATION_PRODUCT Gemcitabine
- DRUG PF-07934040
- COMBINATION_PRODUCT Nab-paclitaxel
- COMBINATION_PRODUCT Cetuximab
- COMBINATION_PRODUCT Fluorouracil
Study Locations (20)
Missouri
- Siteman Cancer Center - St Peters — City of Saint Peters
- Siteman Cancer Center - West County — Creve Coeur
- Siteman Cancer Center - North County — Florissant
- Siteman Cancer Center — St Louis
- Barnes-Jewish Hospital — St Louis
- Washington University School of Medicine — St Louis
- Siteman Cancer Center - South County — St Louis
Colorado
- University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP) — Aurora
- University of Colorado Hospital - Anschutz Outpatient Pavilion — Aurora
- University of Colorado Hospital- Anschutz Cancer Pavilion (ACP) — Aurora
- University of Colorado Hospital — Aurora
Arkansas
- Highlands Oncology Group, PA — Fayetteville
- Highlands Oncology Group, PA — Rogers
- Highlands Oncology Group — Springdale
California
- City of Hope (City of Hope National Medical Center, City of Hope Medical Center) — Duarte
- City of Hope Investigational Drug Service (IDS) — Duarte
North Carolina
- Duke University Medical Center, lnvestigational Chemotherapy Service — Durham
- Duke University Medical Center — Durham
District of Columbia
- Sibley Memorial Hospital — Washington D.C.
Michigan
- START Midwest — Grand Rapids
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 330 participants |
| Start Date | 2024-06-27 |
| Est. Completion | 2028-09-09 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06447662
The ClinicalTrials.gov registry entry for NCT06447662 describes a study currently listed as recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 330 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 769 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 3 conditions, with Carcinoma, Non-Small-Cell Lung appearing as the primary indexed condition, and to 5 interventions — of which Gemcitabine is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06447662 reports 20 study locations spanning 7 distinct geographic areas — top geographies include Missouri, Colorado, Arkansas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06447662 about?
NCT06447662 is a clinical study titled "A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.". The purpose of this study is to learn about the safety and effects of the study medicine alone or when given together with other anti-cancer therapies. This study also aims to find the best dose. This study is seeking participants who have solid tumors (a mass of abnormal cells that forms a lump or...
What is the current status of trial NCT06447662?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 330 participants. The study started on 2024-06-27. Estimated completion is 2028-09-09.
What conditions does trial NCT06447662 study?
This clinical trial studies the following conditions: Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Carcinoma, Pancreatic Ductal. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06447662?
The interventions under investigation include: Gemcitabine (COMBINATION_PRODUCT), PF-07934040 (DRUG), Nab-paclitaxel (COMBINATION_PRODUCT), Cetuximab (COMBINATION_PRODUCT), Fluorouracil (COMBINATION_PRODUCT). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06447662?
This trial is sponsored by Pfizer, which has 769 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06447662 being conducted?
This trial has 20 study locations across Arkansas, California, Colorado, District of Columbia, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.